Revenue from contracts with customers |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Disclosure of disaggregation of revenue from contracts with customers [abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from contracts with customers |
Note 4 — Revenue from contracts with customers Disaggregation of revenue from contracts with customers The principal revenue activities of the Company for the years ended March 31, 2025, 2024 and 2023 were as follows:
For the years ended March 31, 2025, 2024, and 2023, 100% of the revenue derived from the Company's ViraxClear and ViraxVet test kit distribution. Revenues have decreased from the prior year due to the Company's decreasing focus on the ViraxClear and ViraxVet platforms. Accounting policies and significant judgments Management does not consider there to be any significant judgments or estimates in the revenue recognition for the years ended March 31, 2025, 2024 and 2023. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for revenue from contracts with customers. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|